Author:
Auel Britta, ,Goldschmidt Hartmut,Geer Thomas,Moehler Thomas M.,Platzbecker Uwe,Naumann Ralph,Blau Igor,Hänel Mathias,Knauf Wolfgang,Nückel Holger,Salwender Hans-Jürgen,Scheid Christof,Weisel Katja,Gorschlüter Marcus,Glasmacher Axel,Schmidt-Wolf Ingo G. H.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Barlogie B, Smith L (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356
2. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IGH, Gieseler F (1997) Oral idarubicin, dexamethason and vincristine (VID) in the treatment of multiple myeloma. Leukemia 11:22–26
3. Cook G, Sharp RA, Tansey P, Franklin IM (1996) A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 93:931–934
4. Harousseau Jl, Dammacco F, San-Miguel J et al (1999) An alternative treatment for relapsed/resistant multiple myeloma (MM): vinorelbin (VRL) plus high-dose dexamethasone (DEX): two phase II studies. Proc Annu Meet Am Soc Clin Oncol 18 (abstract)
5. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IG, Gieseler F (2004) Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. Haematologica 89(3):371–373
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献